Latest acute leukemia Stories
SAN FRANCISCO, Dec.
TG02 demonstrates ability to mobilize difficult-to-kill leukemic stem cells and render them vulnerable to chemotherapy. San Diego, California (PRWEB) December
--CHOP-Led Pilot Study Engineers Patients' Own Immune Cells to Hunt Down Cancer Cells in Blood-- PHILADELPHIA, Dec.
78 Percent of Patients Treated With BLINCYTO Experienced a Complete Minimal Residual Disease (MRD) Response After One Treatment Cycle THOUSAND OAKS, Calif., Dec.
SAN DIEGO AND TORONTO, Dec.
Interim Data from 33 Evaluable Patients to be Presented at ASH on Saturday SAN DIEGO, Dec. 2, 2014 /PRNewswire/ -- MEI Pharma, Inc.
WHITE PLAINS, N.Y., Dec.
Company expects Induction Response Rate data in Second Quarter of 2015 EWING, N.J., Dec. 1, 2014 /PRNewswire/-- Celator Pharmaceuticals, Inc.
SEATTLE, Dec. 1, 2014 /PRNewswire/ -- CTI BioPharma Corp.
EWING, N.J., Nov. 24, 2014 /PRNewswire/ -- Celator Pharmaceuticals, Inc.
- totally perplexed and mixed up.